<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05095389</url>
  </required_header>
  <id_info>
    <org_study_id>2021-01</org_study_id>
    <nct_id>NCT05095389</nct_id>
  </id_info>
  <brief_title>Adipose Derived Regenerative Cells In the Treatment of Diabetic Foot Ulcers</brief_title>
  <acronym>ASCEND</acronym>
  <official_title>Adipose Derived Regenerative Cells (ADRCs) in the Treatment of Diabetic Foot Ulcers: a Prospective, Double-blind, Multi-center, Randomized, Parallel-group Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paracrine, INC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Paracrine, INC.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Prospective, Double-blind, Multi-center, Randomized, Parallel-group safety and efficacy&#xD;
      study of adipose-derived regenerative cells (ADRCs) in the treatment of patients with&#xD;
      diabetic foot ulcers (DFU).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will have at least one diabetic foot ulcer between 1 cm2 and 16 cm2 area that&#xD;
      remains open despite at least 30 days of DFU care and will need debridement as a part of&#xD;
      their care.&#xD;
&#xD;
      Subjects will be randomly assigned to one of two groups (ADRC Group will receive standard&#xD;
      care plus ADRC, and Control Group will receive standard care plus matched placebo).&#xD;
&#xD;
      ADRCs will be harvested from a small volume liposuction performed on the same day as, but&#xD;
      prior to, the debridement procedure. Fat harvest will occur through small volume&#xD;
      (approximately 100-200 mL) liposuction prior to the surgical debridement procedure on the&#xD;
      same day as the planned autograft procedure.&#xD;
&#xD;
      The lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs&#xD;
      for application to an autograft site. Cells will be delivered via direct injection (minimal&#xD;
      wound penetration with a 22 gauge needle, total volume 5 mL) into the DFU (injected around&#xD;
      the circumference and applied to the base of the ulcer).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2022</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Parallel-Group, Double-Blind, Placebo Controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo is visually indistinguishable from Active Treatment. Every patient receives Standard Care, plus either Active Treatment or Placebo.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>DFU Closure Rate</measure>
    <time_frame>12 Weeks</time_frame>
    <description>The rate of closure at 12 Weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Reduction of Wound Area</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Percent Reduction of Wound Area from Baseline to 12 Weeks for Ulcers not Completely Healed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>Standard Care plus ARDCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will undergo small volume liposuction, and adipose tissue harvested will be processed to ADRCs during same procedure.&#xD;
All patients will receive standard care for their Diabetic Foot Ulcer.&#xD;
Additionally, patients randomized to the ADRC arm will receive ADRCs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care plus Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients will undergo small volume liposuction, and adipose tissue harvested will be processed to ADRCs during same procedure.&#xD;
All patients will receive standard care for their Diabetic Foot Ulcer.&#xD;
Additionally, patients randomized to the Control arm will receive Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ADRCs</intervention_name>
    <description>Administration of Autologous Adipose Derived Regenerative Cells into the Diabetic Foot Ulcer</description>
    <arm_group_label>Standard Care plus ARDCs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard care</intervention_name>
    <description>standard care</description>
    <arm_group_label>Standard Care plus ARDCs</arm_group_label>
    <arm_group_label>Standard Care plus Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Standard Care plus Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  T1D or T2D&#xD;
&#xD;
          -  Diabetic Foot Ulcer, from 1 to 12 months in duration&#xD;
&#xD;
          -  Wagner Grade 1 or Superficial 2&#xD;
&#xD;
          -  Adequate perfusion&#xD;
&#xD;
          -  Able to undergo liposuction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetic Foot Ulcer penetrates to capsule, tendon, or bone&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Non-diabetic neuropathy&#xD;
&#xD;
          -  Significant cardiovascular event within 6 months before screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 15, 2021</study_first_submitted>
  <study_first_submitted_qc>October 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Foot Ulcer</keyword>
  <keyword>DFU</keyword>
  <keyword>Non-healing Foot Ulcer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD/PHI will be made available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

